Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

Por van der Burg, M E L, de Wit, R, van Putten, W L J, Logmans, A, Kruit, W H J, Stoter, G, Verweij, J
Publicado em 2002

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

Por Polee, M B, Eskens, F A L M, van der Burg, M E L, Splinter, T A W, Siersema, P D, Tilanus, H W, Verweij, J, Stoter, G, van der Gaast, A
Publicado em 2002

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Por de Jongh, F E, van Veen, R N, Veltman, S J, de Wit, R, van der Burg, M E L, van den Bent, M J, Planting, ASTh, Graveland, W J, Stoter, G, Verweij, J
Publicado em 2003

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

Por Polee, M B, Hop, W C J, Kok, T C, Eskens, F A L M, van der Burg, M E L, Splinter, T A W, Siersema, P D, Tilanus, H W, Stoter, G, van der Gaast, A
Publicado em 2003

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

Por Schellens, J H M, Planting, ASTh, van Zandwijk, N, Ma, J, Maliepaard, M, van der Burg, M E L, de Boer-Dennert, M, Brouwer, E, van der Gaast, A, van den Bent, M J, Verweij, J
Publicado em 2003